GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » DeferredTaxAndRevenue

Everest Medicines (HKSE:01952) DeferredTaxAndRevenue : HK$0.0 Mil (As of Dec. 2024)


View and export this data going back to 2020. Start your Free Trial

What is Everest Medicines DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Everest Medicines's current deferred tax and revenue for the quarter that ended in Dec. 2024 was HK$0.0 Mil.

Everest Medicines DeferredTaxAndRevenue Historical Data

The historical data trend for Everest Medicines's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Everest Medicines DeferredTaxAndRevenue Chart

Everest Medicines Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial - - - - -

Everest Medicines Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Everest Medicines DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Everest Medicines's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.

Everest Medicines Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Everest Medicines Ltd (HKSE:01952) » Definitions » DeferredTaxAndRevenue
Comparable Companies
HKSE:06826 HKSE:02171 HKSE:02162 HKSE:06855 HKSE:09606 HKSE:09966 HKSE:02410 HKSE:02629 HKSE:00775 HKSE:02105 VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
6HN:Germany
Address
1168 West Nanjing Road, 16th Floor, CITIC Pacific Plaza, Jing’an District, Shanghai, CHN, 200041
Website
https://www.everestmedicines.com
Everest Medicines Ltd is a biopharmaceutical company that integrates discovery, licensing, clinical development, commercialization, and manufacturing of potentially novel or differentiated therapies and vaccines to address critical unmet medical needs initially in the Asia Pacific markets and eventually around the world. Its product pipeline includes; Nefecon (TarpeyoTM), EVER001 (previously known as XNW1011), PTX-COVID19-B, Eravacycline (Xerava), EVER206 (also known as SPR206), and others. Geographically operates in Mainland China.
Executives
Fu Wei 2307 Founder of a discretionary trust who can infl
Nova Aqua Limited 2201 Interest of corporation controlled by you
C-bridge Capital Gp Iv, Ltd. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Gp Iv, L.p. 2201 Interest of corporation controlled by you
C-bridge Healthcare Fund Iv, L.p. 2201 Interest of corporation controlled by you
Tf Capital Iv Ltd. 2201 Interest of corporation controlled by you
C-bridge Capital Gp, Ltd. 2501 Other
C-bridge Healthcare Fund Gp Ii, L.p. 2501 Other
C-bridge Healthcare Fund Ii, L.p. 2501 Other
C-bridge Investment Everest Limited 2501 Other
Tf Capital Ii Ltd. 2501 Other
Everest Management Holding Co., Ltd. 2101 Beneficial owner
Fu Wei 2307 Founder of a discretionary trust who can infl
C-bridge Joint Value Creation Limited 2201 Interest of corporation controlled by you
Kolchinsky Anna Inge Leonore Haas 2202 Interest of your spouse

Everest Medicines Headlines

No Headlines